Kaga, Hajime
Matsumura, Hirotoshi
Saito, Ayano
Saito, Masaya
Abe, Fumito
Suzuki, Takehiro
Dohmae, Naoshi
Odaka, Masafumi
Komatsuda, Atsushi
Wakui, Hideki
Takahashi, Naoto
Article History
Received: 25 October 2022
Accepted: 25 April 2023
First Online: 13 May 2023
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committees of Akita University Hospital (approval number: 1830) and the RIKEN Center (approval number: Wako3 2019-17), and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
: We agree to the publication of this manuscript upon its acceptance and that all copyright ownership for the article will be transferred to Clinical Proteomics. The material submitted is new, original, and has not been submitted to another journal for concurrent consideration.
: Dr. Naoto Takahashi received grants and personal fees from Novartis Pharmaceuticals, Pfizer, and Otsuka Pharmaceutical and grants from Kyowa Kirin, Astellas Pharma, Asahi Kasei Pharma, Ono Pharmaceutical, and Mochida Pharmaceuticals outside of the submitted work. The remaining authors declare that they have no competing interests.